CA1309352C - Methode et composition permettant de reduire le cholesterol serique - Google Patents

Methode et composition permettant de reduire le cholesterol serique

Info

Publication number: CA1309352C
Authority: CA; Canada
Prior art keywords: gel; forming fiber; cholesterol; serum cholesterol; guar gum
Prior art date: 1986-06-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000556790A

Other languages

English (en)

Inventor

Eric H. Kuhrts

Charles E. Day

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hauser-Kuhrts Inc

Original Assignee

Hauser-Kuhrts Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-06

Filing date

1988-01-19

Publication date

1992-10-27

1986-06-06 Priority claimed from US06/871,715 external-priority patent/US4824672A/en

1988-01-19 Application filed by Hauser-Kuhrts Inc filed Critical Hauser-Kuhrts Inc

1988-01-19 Priority to CA000556790A priority Critical patent/CA1309352C/fr

1992-10-27 Application granted granted Critical

1992-10-27 Publication of CA1309352C publication Critical patent/CA1309352C/fr

2009-10-27 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 101
238000000034 method Methods 0.000 title claims abstract description 20
239000000203 mixture Substances 0.000 title claims abstract description 18
230000001603 reducing effect Effects 0.000 title claims abstract description 9
239000000835 fiber Substances 0.000 claims abstract description 31
229920002907 Guar gum Polymers 0.000 claims abstract description 22
239000000665 guar gum Substances 0.000 claims abstract description 22
235000010417 guar gum Nutrition 0.000 claims abstract description 22
229960002154 guar gum Drugs 0.000 claims abstract description 22
229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 17
239000011707 mineral Substances 0.000 claims abstract description 17
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 12
239000001814 pectin Substances 0.000 claims abstract description 10
235000010987 pectin Nutrition 0.000 claims abstract description 10
229920001277 pectin Polymers 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract 6
235000007340 Hordeum vulgare Nutrition 0.000 claims abstract 5
244000090599 Plantago psyllium Species 0.000 claims abstract 5
235000010451 Plantago psyllium Nutrition 0.000 claims abstract 5
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract 3
239000001095 magnesium carbonate Substances 0.000 claims abstract 3
229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract 3
229910000027 potassium carbonate Inorganic materials 0.000 claims abstract 3
235000012000 cholesterol Nutrition 0.000 claims description 21
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
239000012530 fluid Substances 0.000 claims description 6
230000002496 gastric effect Effects 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 5
241000282414 Homo sapiens Species 0.000 claims description 5
239000001569 carbon dioxide Substances 0.000 claims description 5
229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
239000011575 calcium Substances 0.000 claims description 3
239000000796 flavoring agent Substances 0.000 claims description 3
235000019634 flavors Nutrition 0.000 claims description 3
235000003599 food sweetener Nutrition 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 3
239000003765 sweetening agent Substances 0.000 claims description 3
241000209219 Hordeum Species 0.000 claims 4
238000004090 dissolution Methods 0.000 claims 4
231100000252 nontoxic Toxicity 0.000 claims 4
230000003000 nontoxic effect Effects 0.000 claims 4
238000002360 preparation method Methods 0.000 claims 2
230000002335 preservative effect Effects 0.000 claims 2
-1 for example Substances 0.000 abstract description 6
240000005979 Hordeum vulgare Species 0.000 abstract 1
229940107161 cholesterol Drugs 0.000 description 37
108010007622 LDL Lipoproteins Proteins 0.000 description 20
102000007330 LDL Lipoproteins Human genes 0.000 description 20
230000009467 reduction Effects 0.000 description 19
208000029078 coronary artery disease Diseases 0.000 description 13
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
230000000694 effects Effects 0.000 description 12
244000007835 Cyamopsis tetragonoloba Species 0.000 description 10
230000036571 hydration Effects 0.000 description 8
238000006703 hydration reaction Methods 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
108010010234 HDL Lipoproteins Proteins 0.000 description 7
102000015779 HDL Lipoproteins Human genes 0.000 description 7
108010062497 VLDL Lipoproteins Proteins 0.000 description 7
239000006185 dispersion Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000003613 bile acid Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
238000013459 approach Methods 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000036541 health Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
238000011160 research Methods 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
102000004895 Lipoproteins Human genes 0.000 description 3
108090001030 Lipoproteins Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
230000037213 diet Effects 0.000 description 3
235000013325 dietary fiber Nutrition 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
239000003925 fat Substances 0.000 description 3
239000002778 food additive Substances 0.000 description 3
230000000260 hypercholesteremic effect Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000007774 longterm Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
206010049418 Sudden Cardiac Death Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
230000001364 causal effect Effects 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000009862 primary prevention Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
101000848718 Homo sapiens Rap guanine nucleotide exchange factor 5 Proteins 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102100034590 Rap guanine nucleotide exchange factor 5 Human genes 0.000 description 1
206010041969 Steatorrhoea Diseases 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000007211 cardiovascular event Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229940040387 citrus pectin Drugs 0.000 description 1
239000009194 citrus pectin Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
235000012777 crisp bread Nutrition 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000010903 husk Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
235000015263 low fat diet Nutrition 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000276 sedentary effect Effects 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
208000001162 steatorrhea Diseases 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000032258 transport Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000556790A 1986-06-06 1988-01-19 Methode et composition permettant de reduire le cholesterol serique Expired - Lifetime CA1309352C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000556790A CA1309352C (fr)	1986-06-06	1988-01-19	Methode et composition permettant de reduire le cholesterol serique

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/871,715 US4824672A (en)	1986-06-06	1986-06-06	Method and composition for reducing serum cholesterol
CA000556790A CA1309352C (fr)	1986-06-06	1988-01-19	Methode et composition permettant de reduire le cholesterol serique

Publications (1)

Publication Number	Publication Date
CA1309352C true CA1309352C (fr)	1992-10-27

Family

ID=25671668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000556790A Expired - Lifetime CA1309352C (fr)	1986-06-06	1988-01-19	Methode et composition permettant de reduire le cholesterol serique

Country Status (1)

Country	Link
CA (1)	CA1309352C (fr)

1988
- 1988-01-19 CA CA000556790A patent/CA1309352C/fr not_active Expired - Lifetime

Legal Events

Date	Code	Title	Description
2009-10-27	MKEX	Expiry

Publication	Publication Date	Title
US4824672A (en)	1989-04-25	Method and composition for reducing serum cholesterol
US4883788A (en)	1989-11-28	Method and composition for reducing serum cholesterol
Jenkins et al.	1979	Dietary fiber and blood lipids: reduction of serum cholesterol in type II hyperlipidemia by guar gum
Levin et al.	1990	Comparison of psyllium hydrophilic mucilloid and cellulose as adjuncts to a prudent diet in the treatment of mild to moderate hypercholesterolemia
ES2239268T3 (es)	2005-09-16	Composicion que contiene pectina para formar una matriz.
Spilburg et al.	2003	Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterolabsorption and LDL cholesterol
Anderson et al.	1991	Hypocholesterolemic effects of different bulk-forming hydrophilic fibers as adjuncts to dietary therapy in mild to moderate hypercholesterolemia
TW397683B (en)	2000-07-11	Treatment of inflammatory bowel disease using oral dosage forms of <omega>-3 polyunsaturates acids
Brussaard et al.	1981	Blood pressure and diet in normotensive volunteers: absence of an effect of dietary fiber, protein, or fat
JP2002508772A (ja)	2002-03-19	健康補助剤
AU2009200897A1 (en)	2009-03-26	Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides
Tikkanen et al.	2001	Effect of a diet based on low-fat foods enriched with nonesterified plant sterols and mineral nutrients on serum cholesterol
Heijnen et al.	1996	Neither raw nor retrograded resistant starch lowers fasting serum cholesterol concentrations in healthy normolipidemic subjects
JP2005513107A (ja)	2005-05-12	（−）−ヒドロキシクエン酸、クロム、およびギムネマ酸を含有する組成物、および健常体重を促進する方法と関連する健康因子を改善する方法
JPS58501676A (ja)	1983-10-06	微量物質としてセレニウムをヒトに供給するための混合物、ならびに細胞培養のための培地中に器官を保存する溶液および血液成分を保存する栄養溶液におけるその使用
US11554131B2 (en)	2023-01-17	Mixture of HMOs for treating autoimmune diseases
CA2553239A1 (fr)	2007-01-21	Methode de traitement de la steatorrhee chez les enfants
CA1309352C (fr)	1992-10-27	Methode et composition permettant de reduire le cholesterol serique
US20200030267A1 (en)	2020-01-30	Agent for use in the treatment of dyslipidemia
JP2003526661A (ja)	2003-09-09	閉経後の女性および下等動物における脂溶性ビタミンの腸吸収を増進する際の方法
Cerda	1988	The role of grapefruit pectin in health and disease
JP3055930B2 (ja)	2000-06-26	高カリウム血症、高リン血症改善剤
WO2002096393A1 (fr)	2002-12-05	Composition anorexigene a base d'acetate de calcium
JPH09501689A (ja)	1997-02-18	脂肪酸の吸収減少
Dubick	1983	Dietary supplements and health aids—A critical evaluation Part 3—Natural and miscellaneous products